Exclusive Summary

• • A Potential Best-in-class BTK degrader.
• • Capable of degrading both wild-type BTK and multiple drug-resistant mutations arising from clinically approved BTK inhibitors, with in vitro and in vivo activity superior to that of NX5948.
• • Blood-brain barrier (BBB) penetrable.
• • Favorable PK/PD properties, with significantly better oral exposure in humans than NX5948.